Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti(Dana-Farber Cancer Institute), Kathryn C. Arbour(Cornell University), W. Marston Linehan(Massachusetts General Hospital), Amir Vajdi(Dana-Farber Cancer Institute), Natalie I. Vokes(Dana-Farber Cancer Institute), Lingzhi Hong(The University of Texas MD Anderson Cancer Center), Jianjun Zhang(The University of Texas MD Anderson Cancer Center), Michael Tolstorukov(Dana-Farber Cancer Institute), Yvonne Y. Li(Massachusetts Institute of Technology), Liam F. Spurr(Dana-Farber Cancer Institute), Andrew D. Cherniack(Massachusetts Institute of Technology), Gonzalo Recondo(Dana-Farber Cancer Institute), Giuseppe Lamberti(Dana-Farber Cancer Institute), Xinan Wang(Harvard University), Deepti Venkatraman(Dana-Farber Cancer Institute), Joao V. Alessi(Dana-Farber Cancer Institute), Victor R. Vaz(Dana-Farber Cancer Institute), Hira Rizvi(Cornell University), Jacklynn V. Egger(Memorial Sloan Kettering Cancer Center), Andrew J. Plodkowski(Memorial Sloan Kettering Cancer Center), S. Khosrowjerdi(Massachusetts General Hospital), Subba R. Digumarthy(Massachusetts General Hospital), Hyesun Park(Brigham and Women's Hospital), Nuno Vaz(Brigham and Women's Hospital), Mizuki Nishino(Brigham and Women's Hospital), Lynette M. Sholl(Brigham and Women's Hospital), David A. Barbie(Dana-Farber Cancer Institute), Mehmet Altan(The University of Texas MD Anderson Cancer Center), John V. Heymach(The University of Texas MD Anderson Cancer Center), Ferdinandos Skoulidis(The University of Texas MD Anderson Cancer Center), Justin F. Gainor(Massachusetts General Hospital), Matthew D. Hellmann(Cornell University), Mark M. Awad(Dana-Farber Cancer Institute)
Journal of Thoracic Oncology
November 2, 2021
Cited by 364Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis